Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Moderna said Wednesday that its experimental mRNA-based seasonal flu vaccine generated a stronger immune response against four strains of the flu virus than a currently marketed vaccine in a Phase ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 percent higher in participants who were aged 65 years or older. Previous trial ...

Moderna stock rises on flu vaccine data and FDA approvals, while healthcare stocks remain under pressure amid political ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Moderna presented early data from clinical trials of its mRNA-based flu vaccine. The shots didn’t generate more antibodies than shots already on the market.

Moderna, Inc. MRNA announced that it has dosed the first participant in a phase I/II study which is evaluating mRNA-1010, its quadrivalent mRNA-based vaccine candidate, against seasonal influenza.

Moderna started the first trial for its mRNA-based flu vaccine. The success of the mRNA COVID-19 vaccines accelerated work on other shots using the same approach.

Moderna and Pfizer have plans to combine Covid-19 mRNA shots with those for flu and RSV in the years ahead if studies show that they're safe and effective.

(CNN) — Moderna said Wednesday that its experimental mRNA-based seasonal flu vaccine generated a stronger immune response against four strains of the flu virus than a currently marketed vaccine in ...